ReviewCurrent allergy and asthma reports2005
The immunoglobulin E receptor: expression and regulation.
Review in Current allergy and asthma reports, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Neuronal FcεRIα directly mediates ocular itch via IgE-immune complex in a mouse model of allergic conjunctivitis.Journal of neuroinflammation · 2022Article
- Age-Related Cataract Is Associated with Elevated Serum Immunoglobulin E Levels in the South Korean Population: A Cross-Sectional Study.PloS one · 2016Article
- House dust allergy and immunotherapy.Human vaccines & immunotherapeutics · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The interaction of immunoglobulin E (IgE) and its receptors is critical for the manifestation of allergic disease. Currently, IgE receptors include the high-affinity Fc epsilonRI and the low-affinity Fc epsilonRII. Fc epsilonRI is a tetrameric or trimeric complex, and each has distinct expression patterns and unique functional consequences. In general, serum levels of IgE regulate Fc epsilonRI expression, and novel therapies that lower the concentration of IgE have provided insights into the contribution of this receptor in allergic disease. Newer therapies targeting Fc epsilonRI-signaling elements and the low-affinity IgE receptor, Fc epsilonRII (CD23), are being developed.
Indexed as
Identifiers
15842956What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.